Literature DB >> 30538608

Treatment of Hepatocellular Carcinoma With Lenvatinib.

Kwang-Hyub Han1.   

Abstract

Entities:  

Year:  2018        PMID： 30538608      PMCID： PMC6284340     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  7 in total

1.  Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

Authors:  Josep M Llovet; Augusto Villanueva; Anja Lachenmayer; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2015-06-23       Impact factor: 66.675

2.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Authors:  Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

Review 3.  Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.

Authors:  Jessica Zucman-Rossi; Augusto Villanueva; Jean-Charles Nault; Josep M Llovet
Journal:  Gastroenterology       Date:  2015-06-20       Impact factor: 22.682

4.  Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.

Authors:  Eric T Sawey; Maia Chanrion; Chunlin Cai; Guanming Wu; Jianping Zhang; Lars Zender; Alice Zhao; Ronald W Busuttil; Herman Yee; Lincoln Stein; Dorothy M French; Richard S Finn; Scott W Lowe; Scott Powers
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

5.  Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

Authors:  Tim Meyer; Richard Fox; Yuk Ting Ma; Paul J Ross; Martin W James; Richard Sturgess; Clive Stubbs; Deborah D Stocken; Lucy Wall; Anthony Watkinson; Nigel Hacking; T R Jeffry Evans; Peter Collins; Richard A Hubner; David Cunningham; John Neil Primrose; Philip J Johnson; Daniel H Palmer
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-06-23

6.  Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kazuya Kariyama; Koichi Takaguchi; Ei Itobayashi; Noritomo Shimada; Kazuto Tajiri; Kunihiko Tsuji; Toru Ishikawa; Hironori Ochi; Masashi Hirooka; Akemi Tsutsui; Hiroshi Shibata; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Yoichi Hiasa; Kojiro Michitaka
Journal:  Hepatol Res       Date:  2018-10-09       Impact factor: 4.288

7.  Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Jordi Bruix; Tadatoshi Takayama; Vincenzo Mazzaferro; Gar-Yang Chau; Jiamei Yang; Masatoshi Kudo; Jianqiang Cai; Ronnie T Poon; Kwang-Hyub Han; Won Young Tak; Han Chu Lee; Tianqiang Song; Sasan Roayaie; Luigi Bolondi; Kwan Sik Lee; Masatoshi Makuuchi; Fabricio Souza; Marie-Aude Le Berre; Gerold Meinhardt; Josep M Llovet
Journal:  Lancet Oncol       Date:  2015-09-08       Impact factor: 41.316
  7 in total
  2 in total

1.  The Role of Hepatocellular Carcinoma Surveillance in Autoimmune Hepatitis.

Authors:  Ahila Manivannan; Samia Mazumder; Nabil Al-Kourainy
Journal:  Cureus       Date:  2020-10-30

Review 2.  Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma.

Authors:  Saleh A Alqahtani; Massimo G Colombo
Journal:  World J Gastrointest Oncol       Date:  2021-12-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.